| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 187,340 | 159,010 | 138,580 | 127,360 | 112,300 |
| Sales Growth | +17.82% | +14.74% | +8.81% | +13.41% | +5.24% |
| Net Income | -9,960 | -21,720 | -28,950 | -26,990 | -23,790 |
| Net Income Growth | +54.14% | +24.97% | -7.26% | -13.45% | +18.36% |
Axogen Inc (AXGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
AxoGen, Inc. engages in developing and marketing surgical solutions for peripheral nerves. The company's portfolio of products includes Avance Nerve Graft(R), AxoGuard Nerve Connector(R), AxoGuard Nerve Protector(R), Avive Soft Tissue Membrane(R), AcroVal Neurosensory & Motor Testing System(R) and AxoTouch Two-Point Discriminator(R). It operates primarily in the United States, Canada, the United Kingdom, and other European and international countries. AxoGen Inc., formerly known as AxoGen Corp., is based in FL, United States.
Fiscal Year End Date: 12/31